In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck & Ostex drug, diagnostic collaboration, osteoporosis

Executive Summary

Merck is expanding its relationship with Ostex International (bone resorption assay) through an agreement to collaborate on promoting the use of Ostex's OsteoMark with Merck's Fosamax, a Phase III drug for post-menopausal osteoporosis.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Disease Management
    • Includes Equity

Related Companies